Events Partner Content Rational Combinations 360 Addressing key aspects across all facets of combination
Events Partner Content Immuno-Oncology Immuno-Oncology Main Conference: 26 – 27 September 2018 Pre-Conference Workshops: 25 September 2018 Copthorne Tara Hotel, London, UK
News Merck shows canny cancer strategy in $5.76bn Eisai milestone... Firms will co-develop Lenvima and Keytruda combinations
News Immunotherapy arms race latest: Merck buys Viralytics for $3... Big pharma pays 160% premium for Australian biotech
News Groundbreaking lung cancer approval a big boost for AZ's Imf... AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
News Syndax announces further entinostat collaboration with Roche Syndax Pharmaceuticals has announced a new collaboration with Roche’s Genentech unit dedicated to combining small molecule cancer drug entinostat with the latter’s immunotherapy, Tecentriq.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.